Drug Trial Radar · NCT06940700
Clinical Study on the Efficacy and Safety of SHR-4597 Inhalant in Adult Patients With Asthma
Last checked: Nov 19, 2026Latest source record: Apr 23, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
60
Planned (sponsor's estimate)
Start
Apr 2025
Primary completion
Oct 2025
Study completion Dec 2025
Sponsor
- Lead sponsor
- Guangdong Hengrui Pharmaceutical Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Apr 23, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To evaluate the efficacy and safety of SHR-4597 inhalants in adults with asthma: a multicenter, randomized, open-label, positive-controlled Phase II clinical study
Conditions
- Asthma
Interventions
SHR4597Drug
SHR4597
Budesonide inhalantDrug
Budesonide inhalant
Primary outcomes
What the sponsor says the trial is designed to measure.
- Changes in FEV1 (Pre-BD) from baselineTime frame: 6 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
West China Hospital, Sichuan University
Chengdu, Sichuan, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.